Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and Toll-like receptor (TLR) (DC-SIGN and TLR)

Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN/CD209) and Toll-like receptors (TLRs) are two distinct classes of pattern recognition receptors (PRRs) that play synergistic roles in the innate immune system (Geijtenbeek et al., 2000; Akira et al., 2006). DC-SIGN is a C-type lectin receptor that primarily recognizes mannose and fucose carbohydrates on the surface of various pathogens, including HIV-1, Ebola virus, and Mycobacterium tuberculosis (van Kooyk & Geijtenbeek, 2003). TLRs are a family of transmembrane proteins that detect a wide array of pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharides (TLR4) and single-stranded RNA (TLR7/8), to trigger pro-inflammatory signaling cascades (Kawai & Akira, 2011). The crosstalk between these receptors is a critical regulatory mechanism; for example, DC-SIGN signaling through the Raf-1 pathway can refine TLR-induced NF-κB activation, thereby modulating the balance of pro- and anti-inflammatory cytokines like IL-12 and IL-10 (Gringhuis et al., 2007). While several TLR agonists are currently used as vaccine adjuvants (e.g., Monophosphoryl lipid A) or for treating skin conditions and cancers (e.g., Imiquimod), DC-SIGN is primarily targeted in experimental settings to improve the efficacy of dendritic cell-based vaccines and to block viral entry (Banchereau et al., 2012). The therapeutic challenge in targeting this axis lies in achieving potent immune activation against pathogens or tumors without inducing systemic cytokine storms or autoimmune pathology.

Other names

CD209CLEC4LToll-like receptorsTLR familyCD281CD282CD284

Agonism of Toll-like receptors to induce innate immune activation and potential modulation of DC-SIGN for targeted antigen delivery and signaling crosstalk.